Trial Profile
A Randomized, Open-Label Phase 1b Study of ME1100 Inhalation Solution Plus Best Available Therapy in the Treatment of Mechanically Ventilated Subjects With Bacterial Pneumonia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jun 2019
Price :
$35
*
At a glance
- Drugs Arbekacin (Primary)
- Indications Bacterial infections; Pneumonia
- Focus Pharmacokinetics
- Sponsors Meiji Seika Pharma
- 10 Jun 2019 Population pharmacokinetic results from ME1100-CL-102, ME1100-CL-103 and post-marketing study were published in the Antimicrobial Agents and Chemotherapy.
- 03 Jul 2017 Status changed from recruiting to completed.
- 01 Nov 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Mar 2017.